Company Description
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States.
The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, a clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89.
It develops MNPR-101-Lu, a late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225.
The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19.
The company was founded in 2014 and is headquartered in Wilmette, Illinois.
| Country | United States |
| Founded | 2014 |
| IPO Date | Dec 19, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 16 |
| CEO | Chandler Robinson |
Contact Details
Address: 1000 Skokie Boulevard, Suite 350 Wilmette, Illinois 60091 United States | |
| Phone | 847 388 0349 |
| Website | monopartx.com |
Stock Details
| Ticker Symbol | MNPR |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $8.00 |
| CIK Code | 0001645469 |
| CUSIP Number | 61023L108 |
| ISIN Number | US61023L2079 |
| Employer ID | 32-0463781 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Chandler D. Robinson M.B.A., M.D., M.Sc., MBA, MSc | Co-Founder, Chief Executive Officer, President and Director |
| Dr. Christopher M. Starr Ph.D. | Co-Founder and Independent Executive Chairman of the Board |
| Andrew J. Cittadine M.B.A. | Chief Operating Officer |
| Quan Anh Vu | Chief Financial Officer, Principal accounting officer and Principal financial officer |
| Dr. Patrice P. Rioux M.D., Ph.D. | Acting Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 14, 2025 | SCHEDULE 13G/A | Filing |
| Aug 12, 2025 | 8-K | Current Report |
| Aug 12, 2025 | 10-Q | Quarterly Report |
| Jul 14, 2025 | 144 | Filing |
| Jul 14, 2025 | 144 | Filing |
| Jul 14, 2025 | 144 | Filing |
| Jun 23, 2025 | 8-K | Current Report |
| May 23, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| May 14, 2025 | SCHEDULE 13G/A | Filing |
| May 13, 2025 | 10-Q | Quarterly Report |